Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Apremilast
Drug ID BADD_D00156
Description Apremilast, also known as Otezla, is a phosphodiesterase 4 (PDE4) inhibitor used to treat various types of symptoms resulting from certain inflammatory autoimmune diseases. It belongs to the same drug class as [Roflumilast] and [Crisaborole].[A181244,L7495] Initially approved in 2014, it is marketed by Celgene.[L7501] In July 2019, apremilast was granted a new FDA approval for the treatment of oral ulcers associated with Behcet's disease, an autoimmune condition that causes recurrent skin, blood vessel, and central nervous system inflammation.[A181216]
Indications and Usage Investigated for use/treatment in psoriasis and psoriatic disorders.
Marketing Status Prescription
ATC Code L04AA32
DrugBank ID DB05676
KEGG ID D08860
MeSH ID C505730
PubChem ID 10151715
TTD Drug ID D07ESC
NDC Product Code 65977-0119; 60219-1410; 60219-1744; 66406-0240; 66039-934; 70518-3155; 12658-0581; 69766-024; 59572-630; 65372-1204; 59572-631; 55513-369; 58032-2030; 59572-632; 53747-077; 55513-137; 59651-150; 53069-1040; 69766-010; 55513-485; 47621-306; 11722-062; 66406-0241; 46708-902; 65129-1383; 55111-993; 53069-1050; 73309-043; 49187-0757; 66406-0242
Synonyms apremilast | Otezla | CC 10004 | CC10004 | CC-10004
Chemical Information
Molecular Formula C22H24N2O7S
CAS Registry Number 253168-86-4
SMILES CCOC1=C(C=CC(=C1)C(CS(=O)(=O)C)N2C(=O)C3=C(C2=O)C(=CC=C3)NC(=O)C)OC
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Dermatitis allergic10.01.03.014; 23.03.04.003--Not Available
Dermatitis atopic23.03.04.016; 10.01.04.0040.002316%Not Available
Dermatitis bullous23.03.01.002--
Dermatitis contact23.03.04.004; 12.03.01.040; 10.01.01.003--Not Available
Dermatitis exfoliative10.01.01.004; 23.03.07.001--
Dermatomyositis23.03.02.001; 15.05.01.002; 10.04.02.001--Not Available
Diabetes mellitus14.06.01.001; 05.06.01.001--Not Available
Diabetes mellitus inadequate control14.06.01.004; 05.06.01.004--Not Available
Diarrhoea07.02.01.0015.246243%
Diarrhoea haemorrhagic24.07.02.004; 07.02.01.002--Not Available
Diffuse large B-cell lymphoma16.28.02.001; 01.15.02.001--Not Available
Diplopia17.17.01.005; 06.02.06.002--Not Available
Discomfort08.01.08.0030.090902%Not Available
Disorientation19.13.01.002; 17.02.05.015--Not Available
Dissociation19.14.01.002--Not Available
Disturbance in attention19.21.02.002; 17.03.03.001--
Diverticulitis11.01.07.003; 07.10.02.0010.026055%Not Available
Dizziness24.06.02.007; 17.02.05.003; 02.01.02.004--
Dizziness postural24.06.02.008; 17.02.05.004; 02.01.02.005--Not Available
Drug eruption10.01.01.005; 23.03.05.001; 08.01.06.015--Not Available
Drug hypersensitivity10.01.01.001--Not Available
Dry eye06.08.02.001--
Dry mouth07.06.01.002--
Dry skin23.03.03.0010.084533%
Dry throat22.02.05.004; 07.06.01.005--Not Available
Duodenitis07.08.03.001--Not Available
Dysarthria19.19.03.001; 17.02.08.001--
Dysgeusia07.14.03.001; 17.02.07.003--
Dyshidrotic eczema23.03.04.0340.001158%Not Available
Dysmenorrhoea21.01.01.002--
The 7th Page    First    Pre   7 8 9 10 11    Next   Last    Total 40 Pages